Statins are one of the most dangerous drugs prescribed by doctors. The risks from them were obvious before they were ever marketed. Nonetheless, they are among the best selling drugs of all time. Finally, genuine science has been looking at their adverse effects and lack of benefit to document the truth that was obvious from the beginning:
The statin industry, with all of its spin-off(s), is a 20-billion-a-year industry. We are observing the revealing of the utmost medical tragedy of all times. It is unprecedented that the healthcare industry has inadvertently induced life-threatening nutrient deficiency in millions of otherwise healthy people.
The Adverse Effects of Statins
- 307 extra patients suffer from cataracts.
- 23 additional patients develop acute kidney failure.
- 74 extra patients develop liver dysfunction.
- Statins increase muscle fatigue by 30% and cause an 11.3% incidence of rhabdomyolysis at high doses.
- They also state, “What’s more, it induces inflammatory myopathy, including necrotizing autoimmune myopathy with immunosuppression and the statin-related myopathy can last for 12 months.”
- According to the FDA’s adverse event reporting system, about 40 out of every 10,000 statin reports are for interstitial lung disease, which causes scarring in the lungs that is almost never reversible.
- Statins cause hyperglycemia after eating in both diabetics and nondiabetics.
- Statins “induce full blown type 2 diabetes in women.”
- Statins increase the risk of developing HbA1c in people with and without diabetes. HbA1c is a condition that causes glucose to stick to hemoglobin, which is an indicator of greater harm from diabetes.
- Statins prescribed to the elderly cause a 9% increase in diabetes.
- Statins can cause insulin resistance.
- A correlation between Parkinson’s disease and low cholesterol exists, which clearly implicates statins.
- A correlation between statins and early-onset cataracts has been found. Statin users may be 50% more likely to develop cataracts early.
[S]tatin use is associated with an increased prevalence and extent of coronary plaques calcification. Ironically for a drug which was marketed to lower the risk of cardiovascular disease, the confirm registry identified a strong association of statin use to the progression of coronary artery plaque features.